MUC16: Mucin-16
Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. .
- Drugs that act on it: 4
- Approved: 1
- In phases 1 to 3: 3
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on MUC16, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 3
- Antibody-drug conjugate 1
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- CanariaBio Inc.125%
- Menarini Group125%
- Roche125%
| Igovomab | Approved | — | Antibody | Binding agentMucin-16 binding agent | 0 |
| Oregovomab | Phase 3 | CanariaBio Inc. | Antibody | OtherMucin-16 other | 4 |
| Abagovomab | Phase 3 | Menarini Group | Antibody | OtherMucin-16 other | 0 |
| Sofituzumab vedotin | Phase 2 | Roche | Antibody-drug conjugate | Binding agentMucin-16 binding agent | 0 |
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | Oregovomab | Phase 2 | Active, not recruiting | CanariaBio Inc. | Nov 4, 2022 |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | Oregovomab | Phase 2 | Active, not recruiting | CanariaBio Inc. | Apr 20, 2022 |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | Oregovomab | Phase 1 / Phase 2 | Active, not recruiting | CanariaBio Inc. | Jun 24, 2021 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | Oregovomab | Phase 3 | Active, not recruiting | CanariaBio Inc. | Aug 4, 2020 |
- Ovarian cancer0.51
- Asthma0.47
- Alcohol drinking0.44
- Ovarian neoplasm0.38
- Childhood onset asthma0.30
- Peritoneal carcinoma0.29
- Fallopian tube carcinoma0.29
- Ventricular septal defect0.28
- Ovarian dysfunction0.25
- COVID-190.24
- Response to COVID-19 vaccine0.22
- Pancreatic neoplasm0.22
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3580482, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q8WXI7, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets